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Abstract Mastitis is defined as the inflammatory
response resulting of the infection of the udder tissue and it
is reported in numerous species, namely in domestic dairy
animals. This pathology is the most frequent disease of
dairy cattle and can be potentially fatal. Mastitis is an
economically important pathology associated with reduced
milk production, changes in milk composition and quality,
being considered one of the most costly to dairy industry.
Therefore, the majority of research in the field has focused
on control of bovine mastitis and many efforts are being
made for the development of new and effective anti-mas-
titis drugs. Antibiotic treatment is an established compo-
nent of mastitis control programs; however, the continuous
search for new therapeutic alternatives, effective in the
control and treatment of bovine mastitis, is urgent. This
review will provide an overview of some conventional and
emerging approaches in the management of bovine masti-
tis’ infections.
Introduction
Bovine mastitis is the most costly pathology concerning
dairy industry. The economic damages resulting of these
infections are related with direct and indirect losses. The
direct losses include the costs of treatment, discarded milk,
herdsman’s time, fatalities, and the costs associated with
repeated cases of mastitis. The indirect ones include the
decreased milk production, decreased milk quality,
increased culling, loss of premiums, pre-term drying-off,
animal welfare aspects, and other associated health prob-
lems [35]. Numerous pathogens are responsible for mastitis
with the majority of infections caused by the staphylococci,
streptococci, and enterobacteria. There are two types of
mastitis, clinical and subclinical infections, and depending
on the primary reservoir and mode of transmission this
pathology can be contagious or environmental. The main
contagious microorganisms are Staphylococcus aureus and
Streptococcus agalactiae, being their main source the
mammary gland of infected cows. On the other hand, the
primary source of environmental mastitis pathogens is the
habitat of the cow. Streptococcus uberis, Escherichia coli,
and Klebsiella spp. are examples of microorganisms
included in this group [8]. Due to the predominance of
infectious mastitis and to the importance of the use of
antimicrobial agents in the treatment and control of this
pathology, this microbial infection continues to deserve the
attention of several researchers and then continues to be a
subject of investigation by several groups. Therefore, this
review will discuss and focus on old and novel anti-mastitis
strategies that have recently been explored.
Antibiotics
As referred, in the dairy industry, mastitis infections are the
main cause of the usage of antibiotics. Nowadays, antibi-
otic therapy (such as natural or synthetic penicillins) is the
main strategy for mastitis treatment. However, beyond the
costs of its use, the emergence of resistance and the non-
responsiveness of cattle to antibiotics has become a critical
issue. The overuse and misuse of antibiotics in bovine
mastitis may represent a serious problem related with the
emergence of resistance and the entrance of resistant
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bacteria in food chain [49]. Taking this into account,
antibiotic administration is strictly controlled by veteri-
narians in the Nordic countries [46]. In addition, bacteria,
which are able to reside intracellularly, within the mam-
mary gland, and to form abscesses, are more difficult to
combat due to the restriction of their contact with antibi-
otics. This is the case of S. aureus where the percentage of
cure using currently approved antibiotics (e.g., pirlimycin)
is approximately 10–30 %. Bannerman and Wall [3] con-
cluded that therapies available for the treatment of mastitis
caused by S. aureus remain suboptimal and therefore
inefficacious. Moreover, the use of antibiotics has other
disadvantages, as for example the presence of their residues
in the milk which is used for human consumption and
represents a concern to consumers. Therefore, it is urgent
for the search of new antimicrobial therapies, namely non-
antibiotics alternatives in order to minimize their use in
foodborne animals. Moreover, biofilm formation has been
seen as one of the main factors contributing to antibiotic
resistance and recurrent mastitis infections [33]. Atulya
et al. studied the effect of milk composition on biofilm
formation of some of the major mastitis pathogens, and
described that pH was one of the factors that affected
biofilm formation presenting a negative correlation. Once
current therapy is based on the use of acidic antibiotics, the
authors suggested the administration of pH enhancing
agents with the objective of reduce biofilm formation and
consequently long-lasting infections [2]. All these limita-
tions presented by the antibiotics urged the search for new
antimicrobial agents effective against mastitis pathogens.
Some of these alternatives are listed below.
Bacteriophages
Bacteriophage therapy can be a possible alternative to
antibiotics in the fight against mastitis infections. Bacte-
riophages are virus able to infect and kill bacteria [11].
Phages were demonstrated to be determinants as new
antimicrobial agents for veterinary applications. Phage K is
an anti-staphylococcus phage, with lytic and antimicrobial
action and has been used as prophylactic measure in
infections caused by S. aureus. However, to be used as
therapeutic strategy for mastitis it must be active into the
bovine mammary gland and when in contact with raw milk.
This constitutes a disadvantage of phage K that was
inhibited by natural milk and udder secretions [31]. Gill
et al. [20] also tested the efficacy of phage K against S.
aureus. Once again, phage therapy presented several lim-
itations such as degradation/inactivation of phage by milk
and its components (whey proteins) and by the immune
system. Although the results were presented by the previ-
ous studies, some researchers defend that bacteriophage
therapy might be a valid alternative weapon against
mastitis’ pathogens. However, they also defend that more
investigations need to be done namely, in terms of phar-
maco-kinetics and pharmaco-dynamics, as well as studies
concerning the administration of phages into intramam-
mary tissues, aiming to ‘‘exploit phages to their full
potential’’ [4]. Kwiatek et al. isolated a new virulent phage
(MSA6) from a cow with mastitis, which presented a wide
lytic spectrum against staphylococcal strains of bovine
origin. This polyvalent nature of MSA6 is crucial for their
potential use as universal anti-staphylococcal agent.
Moreover, taking into consideration several features pre-
sented by MSA6, this phage is similar to others formerly
used with success in bacteriophage therapy [27]. Every-
thing indicates its possible use in several staphylococci
infections including bovine mastitis. Dias et al. [15] iso-
lated that bacteriophages able to infect S. aureus from
mastitis-positive cows. These phages presented several
features critical to their use as phage therapy, namely wide
range of host, high lytic activity, and thermostability. In
addition, Fenton et al. [18] tested bacteriophage-derived
peptidase; CHAPK against S. aureus isolated from mastitis-
infected cows. This study demonstrated the potential use of
CHAPK as prophylactic and therapeutic measures of mas-
titis infections. CHAPK was effective against biofilms
either by preventing biofilm formation or by disrupting
established biofilms of staphylococci strains associated
with bovine mastitis. Basdew and Laing [5] tested some
phages sensitivity to several simulated stresses. Sabp-P1,
Sabp-P2, and Sabp-P3 were the less sensitive to the stresses
tested in vitro and therefore demonstrated to be the
favorites to future in vivo experiments and to future use as
therapeutic strategy to treat mastitis-infected cows.
Although still with some limitations, in general, bacterio-
phage therapy seems to be a serious candidate to antibiotic
alternatives to be used in the future control and treatment
of bovine mastitis.
Vaccination
During decades an effective vaccine for the prevention of
bovine mastitis was searched. However, the ‘‘miraculous’’
vaccine remains elusive. Some vaccines were developed
against S. aureus mastitis but all presented limited efficacy.
The improper immunization schedules, ineffective adju-
vant formulation, and the limited range of protection are
some of the causes of their ineffectiveness. This last point
is crucial for the formulation of vaccines. It is important to
find a vaccine capable of protecting against a wide range of
strains since multiple strains can be present within a herd
and within an individual cow [3]. Due to its endemic nat-
ure, the large number of microorganisms that can cause the
disease, and the ubiquity of these pathogens, bovine mas-
titis cannot be completely eradicated. Therefore, different
378 F. Gomes, M. Henriques: Control of Bovine Mastitis: Old and Recent Therapeutic Approaches
123
strategies/vaccines are necessary in different countries in
order to respond to the specific requirement of an indi-
vidual country or segment of the dairy industry. Nowadays,
vaccination became an important area in mastitis control
strategies and the implementation of an effective control
protocol is becoming urgent [4]. Some vaccines for S.
aureus were tested but their effect depends of several
factors such as the type of vaccine used, the age of the cow,
and environmental conditions [23, 34]. As example, bac-
terins made from killed bacteria were not effective in the
prevention of new infections of S. aureus. When using a
toxoid as bacterin adjuvant, a higher protective effect was
observed. DNA and recombinant protein vaccines were
developed in alternative to conventional bacterin and as
antibiotic therapy and proved to be active in protecting
mammary glands against S. aureus infections [41, 43, 51].
Seegers et al. [39] demonstrated that when E. coli vacci-
nation was used in the case of environmental mastitis a
higher annual benefit per cow was achieved in comparison
with a non-vaccine approach. Moreover, already in the 90s,
DeGraves and Fetrow [14] also drew attention to the pos-
sible reduction in the losses per cow after immunization.
E. coli J5 is one existing vaccine for coliform mastitis and
is composed of whole antigens derived from J5 mutant
strain of E. coli. This vaccine showed some efficacy and
proved to be able to reduce the number and severity of
coliform mastitis by 70–80 % [12, 50]. There are no vac-
cines available to prevent mastitis caused by K. pneumo-
niae [44]. The mechanisms inherent to the spontaneous
cure that occurs in mild cases of subclinical mastitis can be
exploited to the production of new vaccines [36, 37] and
therefore the research in this area continues.
Nanoparticles
Over the last few years, nanoparticles drew attention of
some investigation groups since these structures can be
used as delivery vehicles for antimicrobial agents. Several
researchers demonstrated that nanoparticles can have
potential use in biomedical applications, namely on bovine
mastitis infections. As example, silver nanoparticles
showed to inhibit S. aureus isolated from subclinical
mastitis [13] and to be ideal for a highly cost-effective
antimicrobial solution. The synergistic effect of silver
nanoparticles and antibiotics was also evaluated, and a
successful combination was obtained using antibiotics that
inhibit protein translation, such as erythromycin, in com-
bination with silver nanoparticles against S. aureus [24].
On the other hand, Wang et al. [48] showed the potential of
tilmicosin-solid lipid nanoparticles against S. aureus.
Xuefeng [47] also reported amoxicillin nanoparticles as
biologically active against S. aureus, E. coli, and S.
agalactiae. Cardozo et al. demonstrated that NO (nitric
oxide)-nanoparticles were able to inhibit S. aureus, and in
general could be used in the treatment and prevention of
bovine mastitis. In addition to the low price, safety NO-
nanoparticles can be an alternative to overcome the prob-
lem of bacterial resistance development [10]. Berni et al.
[7] tested violacein nanoparticles against bovine mastitis.
Violacein was considered a powerful antibactericidal agent
and its nanoparticles were more efficient against S. aureus
than the free agent. In conclusion, antimicrobial agents
encapsulated in nanoparticles and consequently the con-
trolled drug delivery are among the potential strategies to
control and prevent bovine mastitis infections.
Cytokines
The emergence of antibiotic resistance has prompted the
investigation of the immunotherapeutic use of recombinant
cytokines in the treatment of bovine mastitis. Cytokines are
small proteins that have an important role in cell signaling.
Some cytokines (recombinant bovine cytokines, such as
IL-2, IFN-c, and TNF-a) demonstrated to be responsible for
stimulating innate and acquired immunity in mammary
gland. However, this enhanced immunity was not enough
to prevent or treat bovine mastitis. Nevertheless, when
combined with antibiotics, there was an additive effect
being possible their use as adjuvant mastitis therapy [1].
Natural Compounds
Plant-Derived Antimicrobials
As mentioned before, there is an urgent need for alterna-
tives to antibiotics for controlling bovine mastitis. Plants
are promising sources of new biologically active agents
with antimicrobial action. Moreover, plant-derived drugs
have the advantage of not inducing resistance after pro-
longed exposure [16, 32]. Some examples of plant-derived
natural compounds are diterpenes. Fonseca et al. tested
three diterpenes: manool, ent-kaurenoic acid, and ent-
copalic acid against several bovine mastitis pathogens. Ent-
copalic acid (CA) was the most active against most of the
microorganisms tested. Besides its antibacterial potential,
CA did not to cause a cytotoxic effect on human fibroblast
cell line, so this fact encourages its possible use on bovine
mastitis control and treatment [19]. Baskaran et al. [6] also
investigated the antimicrobial activity of plant-derived
molecules on a wide array of bacterial mastitis pathogens
in milk, namely, Streptococcus agalactiae, Streptococcus
dysgalactiae, Streptococcus uberis, S. aureus, and E. coli.
This in vitro study demonstrated that all plant-derived
molecules (trans-cinnamaldehyde (TC), eugenol, car-
vacrol, and thymol) were effective against all microor-
ganisms tested being TC the most effective. Since it was
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classified as safe by the United States Food and Drug
Administration and presented encouraging results against
the major bacterial mastitis pathogens, it was suggested by
Baskaran et al. [6] as a potential alternative/adjuvant to
antibiotics in the prevention and treatment of bovine
mastitis. Additionally, ethanolic extracts of propolis (EEP),
which are a resinous mixture collected by honeybees from
parts of plants, were tested against S. aureus. These
extracts were biologically active against this mastitis
pathogen. However, when tested in cells cultivated in milk,
a lower inhibitory effect was observed, concluding the
authors that milk component affect the antimicrobial
activity of EEP. Nevertheless, given their results and taking
into consideration that propolis-resistance appears to be a
phenotype not easily selected, the authors suggested that
EEP might be a potential antimicrobial agent for mastitis
control in vivo [38]. Khayatnouri and Topchi [25] tested
the effect of monolaurin, a food grade glycerol monoester
of lauric acid found in coconut oil, on S. aureus isolates
from bovine mastitis. Once again this compound demon-
strated antibacterial effect against S. aureus. Gopinath et al.
[21] tested the effect of Tabernaemontana divaricata (L.)
extracts on a panel of microorganisms responsible for
bovine mastitis. A significant antibacterial effect was
observed on all bacteria studied. This preliminary research
drew the attention to the possible use of natural compounds
from Tabernaemontana divaricata (L.) as anti-mastitis
drug. In vitro tests conducted by Tolosa et al. [45]
demonstrated that crude extracts of two medicinal plants,
Combertum molle and Commicarpus pedenculosus,
showed to have a good antimicrobial effect against S.
aureus isolated from bovine clinical mastitis.
Moreover, extracts from twenty medicinal plants were
tested by Doss et al. against a wide array of infectious
agents responsible for bovine mastitis. These extracts were
active against the microorganisms tested [17, 30]. Centella
asiatica is another plant with a wide array of antimicrobial
agents such as triterpenes. Crude extracts of this plant were
tested against S. aureus isolated from mastitis-infected
cows. Ethanol extracts demonstrated to be biologically
active against the strains tested. Although the authors
suggest more studies namely in vivo, they drew attention of
the potential use of these compounds and consequently of
this plant as future alternative of antibiotics [42]. Plant
antimicrobial peptides (PAP) (c-thionin and thionin
Thi2.1), produced by bovine endothelial cells, were tested
on intracellular S. aureus. These antimicrobial peptides
showed to be effective against this pathogen and therefore
seem to be an attractive and potential antimicrobial
approach to prevention and treatment of intracellular
infections, namely intracellular S. aureus bovine mastitis.
Additionally to their antimicrobial activity, c-thionin and
thionin Thi2.1, works as immunomodulators [29]. In
general, all these studies showed positive results when
testing herbal extracts on mastitis-causing pathogens and
allowed to suggest the potential use of several plants as a
sustainable alternative treatment to replace antibiotics.
Animal-Derived Antimicrobials
The use of immunomodulators, naturally produced by
mammals, such as lactoferrin, was appointed as potential
non-antibiotic antimicrobial agents for treatment and pre-
vention of bovine mastitis. Lactoferrin is a glycoprotein
found in several body secretions such as saliva, tears,
bronqueal mucus, and milk. This molecule exhibited an
antibacterial effect against some major mastitis-causing
pathogens namely E. coli, S. aureus, coagulase-negative
staphylococci, Pseudomonas aeruginosa and K. pneumonia
[26]. Hafez et al. also isolated lactoferrin from bovine milk
whey and tested its antimicrobial potential against S. aur-
eus, E. coli, S. agalactiae, and P. aeruginosa. Lactoferrin
showed a significant inhibitory effect against all isolates
tested being more effective against E. coli and less effec-
tive against S. aureus [22]. In general, their results are in
accordance with the work of Kutila et al. [26] and also
suggest the possible use of lactoferrin as antimicrobial and
immunomodulator agent. b-Lactoglobulin is a protein
present in the whey of most mammals. When tested against
several mastitis-causing pathogens this protein showed an
inhibitory effect on S. aureus and S. uberis. When tested in
combination with lactoferrin an additive effect was
observed against S. aureus. In addition to the increased
combined effect of these two proteins, the fact that they
have different effect on different bacteria can
enlarge/complement the spectrum of antimicrobial activity.
In addition, marine sponges are described as a source of
new antimicrobial agents. Extracts of these sessile aquatic
animals presented inhibitory activity against several spe-
cies of coagulase-negative staphylococci (CNS) isolated
from bovine mastitis cases. Among the marine sponges
tested, Cinachyrella sp., Haliclona sp., and Petromica
citrine were active against 61 % of the microorganisms
studied, being the extracts of P. citrine the most effective
against CNS strains [28].
Bacteria and Bacteria-Derived Antimicrobials
Natural compounds produced by bacteria and presenting
antimicrobial action are also suggested by several
researchers as potential option for alternative antibiotics for
the control and treatment of bovine mastitis. Weisella
confusa (lactic acid bacteria) and its metabolites demon-
strated to be active against S. aureus and S. agalactiae [40].
S. aureus is one of the most common etiological agents in
mastitis of cows. The success rate of antibiotic treatment is
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low due to the ability of S. aureus to penetrate the mam-
mary gland tissue and form abscesses. Taking this into
consideration, Bouchard et al. [9] tested live lactobacillus
casei as mammary probiotics. In fact, these bacteria were
able to prevent the internalization of S. aureus into mam-
mary epithelial cells and therefore are appointed as possi-
ble strategy to reduce chronicity and recurrence of S.
aureus mastitis infections.
Conclusions
Currently, the administration of antibiotics is the most
common method of treatment of bovine mastitis. However,
this kind of strategy has some disadvantages including low
cure rate, increasing occurrence of resistance, and the
presence of antibiotics residues in the milk. Therefore, a
wide array of alternatives to antibiotics was investigated by
several groups of researchers in order to find an effective
approach for management of bovine mastitis. Bacterio-
phages, vaccines, nanoparticles, cytokines, and natural
compounds from plants, animals, and bacteria are some
examples of valid substitutes to antibiotics. In vitro studies
showed encouraging results but more tests, namely in vivo,
are still critical.
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